Pfizer Discontinues Premarin Vaginal Cream in Canada Amid Broader Hormone Therapy Shortages
Pfizer has stopped selling Premarin vaginal cream in Canada following an internal review, citing no safety or efficacy concerns. While existing stocks of Premarin tablets are expected to last until mid-2027, the move adds pressure to a Canadian menopause drug supply already strained by shortages of estradiol patches and rising global demand for hormone replacement therapy.
Pfizer will no longer sell its hormone replacement therapy Premarin in Canada following an internal review. The company confirmed it will stop marketing both Premarin vaginal cream and Premarin tablets, though existing inventories of the tablets are expected to remain available through mid-2027. 
Premarin contains a mixture of estrogen hormones prescribed to treat vaginal dryness, painful intercourse, and other menopause symptoms. According to Pfizer, the decision to discontinue the products was not related to new safety, efficacy, or quality concerns. Premarin Intravenous, which is used in hospitals for abnormal uterine bleeding, is not affected by the discontinuation.
The vaginal cream has been unavailable in Canada since June and will not be returning. Existing stocks of Premarin tablets in 0.3 mg, 0.625 mg, and 1.25 mg strengths are expected to last until about mid-2027. Pfizer stated that its latest decision applied only to Canada and declined to comment on other markets. This follows a separate action in July, when Pfizer suspended sales of Premarin vaginal cream in India due to a supply disruption.
The removal of Premarin vaginal cream contributes to broader supply constraints for menopause hormone therapies in Canada. Health Canada reported that certain strengths of estradiol transdermal patches made by Bayer and Sandoz Canada were in short supply, with intermittent shortages expected until early 2027. The discontinuation of Premarin products could add further pressure on Canada's menopause drug supply. 
These supply challenges occur as demand for hormone replacement therapy has risen, particularly in the United States, following the U.S. Food and Drug Administration's removal of long-standing safety warnings in November 2025. Unmanaged menopause symptoms currently cost Canada's economy $3.5 billion.